Browse our latest Medicine articles

There are common seminal microbiome clusters in both healthy men and those with infertility and recurrent pregnancy loss, and some specific microbiota perturbations are associated with impaired semen quality.

Endothelial-specific supplementation with Aff3ir-ORF2 significantly ameliorated disturbed flow-induced endothelial activation and the development of atherosclerotic plaques, highlighting its promising therapeutic potential for the treatment of atherosclerosis.

Simply crushed zizyphi spinosi semen not only ameliorates Aβ, tau, and α-synuclein pathology in dementia model mice, but also rejuvenates brain function by suppressing cellular senescence in normal aged mice.

Reserpine, previously identified through high-throughput screening in CEP290 retinal degeneration models, enhances photoreceptor survival in P23H rhodopsin retinal degeneration models, particularly in female rats, indicating its gene-agnostic and sex-specific effectiveness.

Transition from healthy to diseased state is a cell-type-specific process, influenced by neighboring cells and resulting in functionally meaningful differences between pulmonary artery adventitial fibroblasts and smooth muscle cells.

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Exogenous mitochondrial transplantation improves cardiac function after cardiopulmonary resuscitation (CPR) may be related to improving mitochondrial function, reducing the oxidative stress response, and decreasing apoptosis in myocardial cells.

A comprehensive proteomic map of liver fibrosis progression and healing in two mouse models identifies etiology-specific extracellular matrix components, laying the foundation for targeted antifibrotic therapies.

CCR5 antagonists show promise for stroke cerebroprotection and recovery, although further preclinical evidence in clinically relevant domains could strengthen support for clinical translation.

Kaplan–Meier curves showed that extended adjuvant pyrotinib administered after trastuzumab-based adjuvant therapy provides a promising survival benefit in patients with high-risk HER2-positive breast cancer.